GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update
March 15 2021 - 09:00AM
via NewMediaWire --
GeoVax Labs,
Inc. (NasdaqCM: GOVX), a biotechnology company
developing human immunotherapies and vaccines against infectious
diseases and cancer, announces today that it plans to report 2020
financial results on Tuesday, March 23, 2021 after the market
closes.
Management will host a conference call at 8:00
a.m. ET on Wednesday, March 24, 2021 to review financial results
and provide an update on corporate developments. Following
management’s formal remarks, there will be a question and answer
session.
Participants are asked to pre-register for the
call via the following
link: https://dpregister.com/sreg/10152894/e3a3a9bd2c
Please note that registered participants will
receive their dial-in number upon registration and will dial
directly into the call without delay. Those without Internet
access or who are unable to pre-register may dial in by calling
1-866-777-2509 (domestic) or 1-412-317-5413 (international).
All callers should dial in approximately 10 minutes prior to the
scheduled start time and ask to be joined into the GeoVax Labs
call.
The conference call will be available through a
live webcast found here:
https://services.choruscall.com/links/govx210324.html
A webcast replay of the call will be available
approximately one hour after the end of the call through June 24,
2021. The webcast replay can be accessed through the above
links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088
(international) and using access code 10149661. The telephonic
replay will be available until April 7, 2021.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines against infectious
diseases and cancer using a novel patented Modified Vaccinia
Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On
this platform, MVA, a large virus capable of carrying several
vaccine antigens, expresses proteins that assemble into VLP
immunogens within (in vivo) the person receiving the vaccine. The
production of VLPs in the person being vaccinated can mimic virus
production in a natural infection, stimulating both the humoral and
cellular arms of the immune system to recognize, prevent, and
control the target infection. The MVA-VLP derived vaccines can
elicit durable immune responses in the host similar to a
live-attenuated virus, while providing the safety characteristics
of a replication-defective vector.
GeoVax’s current development programs are focused
on preventive vaccines against COVID-19, HIV, Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and
malaria, as well as therapeutic vaccines against multiple cancers.
The Company has designed a preventive HIV vaccine candidate to
fight against the subtype of HIV prevalent in the commercial
markets of the Americas, Western Europe, Japan, and Australia;
human clinical trials for this program are managed by the HIV
Vaccine Trials Network (HVTN) with the support of the National
Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of
two separate collaborative efforts to apply its innovative gene
therapy approach toward a functional cure for HIV.
Cautionary Note
Regarding Forward-Looking Statements
This release and the related conference call
contain forward-looking statements regarding GeoVax’s business
plans and financial resuls.. The words “believe,” “may,”
“estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,”
“could,” “target,” “potential,” “is likely,” “will,” “expect” and
similar expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements largely on our current expectations and projections
about future events and financial trends that we believe may affect
our financial condition, results of operations, business strategy
and financial needs. Actual results may differ materially from
those included in these statements due to a variety of factors,
including whether: GeoVax can develop and manufacture its vaccines
with the desired characteristics in a timely manner, GeoVax’s
vaccines will be safe for human use, GeoVax’s vaccines will
effectively prevent targeted infections in humans, GeoVax’s
vaccines will receive regulatory approvals necessary to be licensed
and marketed, GeoVax raises required capital to complete vaccine
development, there is development of competitive products that may
be more effective or easier to use than GeoVax’s products, GeoVax
will be able to enter into favorable manufacturing and distribution
agreements, the impact of the COVID-19 pandemic continues, and
other factors, over which GeoVax has no control.
GeoVax Labs,
Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Feb 2024 to Mar 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Mar 2023 to Mar 2024